Teladoc (TDOC) Q1 Revenue Misses Consensus, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Needham Starts NeoVolta (NEOV) at Buy
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- SanDisk stock target lifted by Citi on continued demand strength
Teladoc Health Reports First Quarter 2022 Results
April 27, 2022 4:05 PM EDTFirst quarter revenue grows 25% year-over-year to $565.4 million Net loss per share of $41.58, primarily driven by non-cash goodwill impairment charge of $6.6 billion or $41.11 per shareFull year guidance ranges for 2022 revenue, net loss per share and adjusted EBITDA revised to $2.4 - $2.5 billion, ($43.50) per share - ($43.00) per share, and $240 - $265 million, respectively
PURCHASE, NY, April 27, 2022 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in... More
